According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “
A number of other equities analysts also recently commented on the company. HSBC set a $46.00 price objective on Aqua America and gave the stock a buy rating in a research report on Friday, June 28th. BNP Paribas reiterated a neutral rating on shares of RECKITT BENCKIS/S in a research report on Friday, July 5th. Finally, Societe Generale downgraded RECKITT BENCKIS/S from a buy rating to a sell rating in a research report on Tuesday, July 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. RECKITT BENCKIS/S presently has a consensus rating of Hold and a consensus price target of $19.00.
RECKITT BENCKIS/S Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Read More: Total Return
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.